Abbott Laboratories Hovers Just Above 52-Week Low as Shares Struggle to Find a Floor

By TrendSpider Editor

Abbott Laboratories (ABT) is trading at $89.54 on Monday, May 4, 2026, just cents above its 52-week low of $89.135 set during the prior session, as the stock continues to face significant downward pressure. Friday's session saw shares oscillate between $89.135 and $91.00 before today's fractional 0.

Abbott Laboratories Hovers Just Above 52-Week Low as Shares Struggle to Find a Floor

Abbott Laboratories (ABT) is trading at $89.54 on Monday, May 4, 2026, just cents above its 52-week low of $89.135 set during the prior session, as the stock continues to face significant downward pressure. Friday's session saw shares oscillate between $89.135 and $91.00 before today's fractional 0.09% gain offered little relief. With the 52-week high sitting at $139.05, ABT has shed a substantial portion of its value over the past year, raising questions about whether the stock has found a durable bottom or is simply pausing before another leg lower.

Key Drivers of the ABT Stock Move

The forward setup for ABT remains cautious. The stock's prolonged slide from $139.05 to current levels represents a drawdown of nearly 36% over the past 52 weeks, a move that has placed Abbott firmly in distressed technical territory. Investors will be watching closely to see whether the $89.135 level holds as meaningful support or merely represents a temporary pause. Any broader market volatility or sector-level weakness in healthcare and medical devices could easily push shares through that floor, while a stabilization here combined with positive company-specific developments could serve as the foundation for a recovery attempt. Volume and momentum data in the sessions ahead will be critical indicators of which scenario is more likely to unfold.

ABT Seasonality

Historically, early May can be a transitional period for large-cap healthcare names, often influenced by post-earnings repositioning and sector rotation as the market moves deeper into the second quarter. Given that ABT is testing multi-year lows at this juncture, seasonal patterns carry added weight as traders assess whether the stock can stabilize heading into the summer months.

ABT Relative Performance

ABT's current price of $89.54 places it at the extreme low end of its 52-week range of $89.135 to $139.05, underperforming many of its large-cap medical device peers that have not seen comparable drawdowns over the same period. The stock's inability to stage a meaningful bounce despite being near a full-year low suggests that sector-level tailwinds have not been sufficient to offset the stock-specific selling pressure that has defined Abbott's price action in recent months.